Development and Validation of a Nomogram for Predicting the Severity of the First Episode of Hyperlipidemic Acute Pancreatitis
Yongxu Lin,Yaling Liu,Qiuyan Lin,Mingrong Wang,Pingying Jiang,Kaiyi Mao,Fenglin Chen,Jian Ding,Dan Li
DOI: https://doi.org/10.2147/jir.s459258
IF: 4.5
2024-05-21
Journal of Inflammation Research
Abstract:Yongxu Lin, 1, 2 Yaling Liu, 3 Qiuyan Lin, 1, 2 Mingrong Wang, 1, 2 Pingying Jiang, 1, 2 Kaiyi Mao, 1, 2 Fenglin Chen, 1, 2 Jian Ding, 3 Dan Li 1, 2 1 Department of Gastroenterology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China; 2 Fujian Clinical Research Center for Digestive System Tumors and Upper Gastrointestinal Diseases, Fuzhou, People's Republic of China; 3 Department of Gastroenterology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China Correspondence: Dan Li, No. 29 Xinquan Road, Fuzhou, 350001, People's Republic of China, Email Jian Ding, No. 20 Chazhong Road, Fuzhou, 350005, People's Republic of China, Email Purpose: Early detection of hyperlipidemic acute pancreatitis (HLAP) with exacerbation tendency is crucial for clinical decision-making and improving prognosis. The aim of this study was to establish a reliable model for the early prediction of HLAP severity. Patients and Methods: A total of 225 patients with first-episode HLAP who were admitted to Fujian Medical University Union Hospital from June 2012 to June 2023 were included. Patients were divided into mild acute pancreatitis (MAP) or moderate-severe acute pancreatitis and severe acute pancreatitis (MSAP+SAP) groups. Independent predictors for progression to MSAP or SAP were identified through univariate analysis and least absolute shrinkage and selection operator regression. A nomogram was established through multivariate logistic regression analysis to predict this progression. The calibration, receiver operating characteristic(ROC), and clinical decision curves were employed to evaluate the model's consistency, differentiation, and clinical applicability. Clinical data of 93 patients with first-episode HLAP who were admitted to the First Affiliated Hospital of Fujian Medical University from October 2015 to October 2022 were collected for external validation. Results: White blood cell count, lactate dehydrogenase, albumin, serum creatinine, serum calcium, D-Dimer were identified as independent predictors for progression to MSAP or SAP in patients with HLAP and used to establish a predictive nomogram. The internally verified Harrell consistency index (C-index) was 0.908 (95% CI 0.867– 0.948) and the externally verified C-index was 0.950 (95% CI 0.910– 0.990). The calibration, ROC, and clinical decision curves showed this nomogram's good predictive ability. Conclusion: We have established a nomogram that can help identify HLAP patients who are likely to develop MSAP or SAP at an early stage, with high discrimination and accuracy. Keywords: early prediction, nomogram, hyperlipidemic acute pancreatitis, risk factor, prognosis Acute pancreatitis (AP) refers to a common inflammatory disease of the pancreas caused by aberrant activation of pancreatic enzymes characterized by local inflammation of the pancreas and subsequent systemic inflammatory response. It is a prominent digestive emergency that leads to hospitalization. 1,2 The common causes of AP encompass biliary diseases, hyperlipidemia, and alcohol consumption. AP caused by serum triglyceride (TG) levels ≥11.30 mmol/L or between 5.65 and 11.30 mmol/L with lipid turbidity is called hyperlipidemic acute pancreatitis (HLAP). With the improvement of living standards and changes in dietary structure, the incidence of HLAP is increasing daily, and HLAP is becoming more severe and affects people at a younger age, which requires vigilance. 3 HLAP has a high incidence of complications and poor prognosis. 4 The incidence of local complications, acute renal failure, and exacerbation in patients with HLAP is higher than that in patients with non-HLAP. 3 Therefore, it is imperative to stratify patients with HLAP based on their risk level in order to facilitate clinical decision-making and optimize treatment administration. Currently, the revised Atlanta Classification in 2012 is employed for grading the severity of AP, 5 but there exists a delay in its implementation. Additionally, there are several scoring systems for early assessment of AP severity, including the Ranson score, Acute Physiology and Chronic Health Evaluation (APACHE) II score, modified computed tomography severity index (MCTSI), and Bedside Index for Severity in Acute Pancreatitis (BISAP) score. 6–8 However, these scoring systems also exhibit specific drawbacks and limitations. Considering the aforementioned predictive models' limitations and HLAP's unique pathogenesis and clinical characteristics, there are currently few repo -Abstract Truncated-
immunology